

# CoNCERT Pharmaceuticals Inc.®

Concert Pharmaceuticals  
Investor Relations Department  
99 Hayden Avenue, Suite 500  
Lexington, MA 02421  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

**NASDAQ: CNCE**

Last Trade:	14.66
Trade Time:	4:00 PM ET Jun 26, 2017
Change:	0.13 <span style="color: green;">▲</span> (+0.895%)
Day Range	14.20 - 14.85
52-Week Range	7.11 - 19.11
Volume	135,526


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

At Concert Pharmaceuticals, we are pioneering our industry-leading expertise in deuterium chemistry to discover and develop innovative drug products that have impact for patients and address important medical needs. Our innovative approach has already resulted in multiple drug candidates that offer improved ways to target a broad range of disease areas, including CNS disorders, renal disease, inflammation and cancer. Each of these novel candidates was designed to be improved with our deuterium chemistry, and is based on an approved drug, an advanced clinical candidate or a previously studied, biologically active compound.

[\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Jun 12, 2017

[Concert Pharmaceuticals Announces \\$30 Million Venture Debt Financing from Hercules Capital](#)

May 30, 2017

[Concert Pharmaceuticals to Present at Upcoming Investor Conferences](#)

May 30, 2017

[Concert Pharmaceuticals Announces Departure of Chief Financial Officer, Ryan Daws](#)

May 24, 2017

[Concert Pharmaceuticals Announces Shareholder Approval of CTP-656 Asset Purchase Agreement with Vertex Pharmaceuticals](#)

May 22, 2017

[Concert Pharmaceuticals Receives Second Request from FTC Under HSR Act](#)

## Financials [\[ View all \]](#)

Apr 26, 2017

[Proxy Statement \(DEF 14A\)](#)

May 2, 2017

[Quarterly Report \(10-Q\)](#)